RemeGen Co., Ltd. — Capital/Financing Update 2021

Nov 4, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [169 x 52] intentionally omitted <==

RemeGen Co., Ltd. 榮昌生物製藥（煙台）股份有限公司*

(A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 9995)

INSIDE INFORMATION

This announcement is made by RemeGen Co., Ltd.* (the “ Company ”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “ Stock Exchange ”) (the “ Listing Rules ”) as well as the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated May 10, 2021 and June 21, 2021 and the circular of the Company dated May 13, 2021 containing, among other things, related matters of the proposed initial public offering of A shares and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange by the Company (the “ Proposed Issue of A Shares ”). Unless otherwise defined, capitalized terms used in this announcement shall have the meanings as defined in the abovementioned announcements and circular.

The submission proof prospectus in relation to the Company’s Proposed Issue of A Shares has been published on November 4, 2021 on the website of the Review and Approval of the Issuance and Listing of Stocks on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (上 交所科創板股票發行上市審核網站) at kcb.sse.com.cn. This announcement sets out an extract of the preliminary estimation on the Company’s certain key financial information for the nine months ended September 30, 2021 as well as the material changes subsequent to the last audited financials ended June 30, 2021 contained in the submission proof prospectus. The submission proof prospectus is only a proof and the proof and information contained therein are subject to the finalization of the prospectus.

Figures and information contained in this announcement do not constitute a profit forecast or result guarantee, and may differ from the actual results of the Company due to various uncertainties. They are prepared based on the China Accounting Standards for Business Enterprises, have not been audited or reviewed, and do not represent the Company’s operating income and net profit to be realized eventually. Such information do not constitute actual commitments to potential investors and shareholders of the Company. Potential investors and shareholders of the Company should be aware that inappropriate reliance on and usage of such information may expose to investment risks. Shareholders of the Company and potential investors are reminded to exercise caution when dealing in the securities of the Company.

1

Preliminary Estimation of the Key Financial Information for the Nine Months ended September 30, 2021:

According to the preliminary estimation, the Company is expected to record an operating revenue of approximately RMB110 million to RMB120 million for the period from January to September 2021, representing a year-on-year increase of approximately 5,039.7% to 5,506.9%; the net loss attributable to the shareholders of the parent company is expected to be RMB-690 million to RMB-680 million, with a year-on-year increase of 59.2% to 61.5%; the net loss attributable to the shareholders of the parent company after deducting non-recurring gains and losses is expected to be RMB-690 million to RMB-680 million, representing a year-on-year increase of 45.6% to 47.7%.

The operating revenue of the Company for the period from January to September 2021 has increased significantly as compared with the same period last year, mainly due to the sales of the core products of the Company, namely, telitacicept and disitamab vedotin, after the conditional marketing approval from the National Medical Products Administration for the same were obtained in March and June 2021, respectively, while the Company did not launch any product during the same period in 2020, and the revenue from principal business was RMB0; The Company’s net loss attributable to shareholders of the parent company and net loss attributable to shareholders of the parent company after deducting non-recurring gains and losses increased significantly in the period from January to September 2021 over the same period of the previous year, mainly due to the Company’s continuous large-scale investment in research and development activities resulting in the increase of approximately 65% in research and development expenses during the period from January to September 2021 as compared with the same period last year, and that the sales revenue can not make up the Company’s overall costs and expenses as the launch of the Company’s commercialized products as abovementioned is still very recent.

The above estimated results for the period from January to September 2021 are only the preliminary estimation results of the Company, which have not been audited or reviewed by the accountants of the Company, and do not represent the final operating revenue and net profit to be realized by the Company, nor do they constitute a profit forecast or performance commitment of the Company.

The English version of this announcement is an informal translation of its Chinese version. In case of any discrepancy, the Chinese version shall prevail.

2

As the Proposed Issue of A Shares is subject to certain conditions precedent, it may or may not be completed. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company. Further announcement will be made by the Company as and when appropriate in respect of the Proposed Issue of A Shares. This announcement is for information purposes only and does not constitute an invitation or an offer to acquire, purchase or subscribe for the securities of the Company.

By order of the Board RemeGen Co., Ltd. Mr. Wang Weidong* Chairman and executive director

Yantai, the People’s Republic of China November 4, 2021

As at the date of this announcement, the Board of the Company comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, Ms. Yu Shanshan, Mr. Hao Xianjing and Dr. Ma Lan as the independent non-executive Directors.

• For identification purposes only

3